Vytrus Biotech says European skin rejuvenation patent validated in seven countries

• Vytrus Biotech secured national validation in seven European markets for its EP 3283092 skin rejuvenation or wound-healing patent.
• Patent granted on April 29, 2026; protection runs until April 11, 2036.
• Europe represented 70% of 2025 sales, reinforcing the strategic value of expanded patent coverage in the region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vytrus Biotech SA published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.